Fabio Girardi, Consultant Medical Oncologist at Veneto Oncology Institute IOV – IRCCS, shared a post on LinkedIn:
“Yesterday, at the San Antonio Breast Cancer Symposium, we presented our population-based, high-resolution study exploring outcomes and patterns of care across the continuum of estrogen receptor (ER) expression, while accounting for treatment details and tumour characteristics.
The evidence at the population level to date is scarce, mainly for patient subgroups currently underrepresented at the clinical trial level, such as women with ER-low tumours.
Key methods:
– Detailed pathology data from two large, long-standing population-based Italian cancer registries.
– Record linkage with population-based claims and drug prescription datasets.
– Stratifications by ER expression: 0% (TNBC), 1-9% (ER-low), 10-49%, and ≥50%.
– Collection of validated cause-of-death data to estimate cancer-specific survival.
Key findings:
– 10,155 patients diagnosed between 2014 and 2021, with follow-up until 2024.
– Endocrine therapy and chemotherapy rates varied across groups. In the ER-low subgroup, up to 30% of the patients received endocrine therapy.
– Three-year cancer-specific survival was 91% for TNBC, 93% for ER-low, 95% for ER 10-49%, and 98% for ER ≥50%.
– At five years, survival declined to 84% for TNBC, stabilised around 90% for ER-low and ER 10-49%, and remained at 95% for ER ≥50%.
– TNBC and ER-low BC showed similar short-term outcomes but different long-term trajectories.
But: Larger studies are needed to validate these results. More to come!
Coauthors: Stefano Guzzinati, Maria Vittoria Dieci, Pietro Napolitano, Luigino Dal Maso, Fabio Puglisi, Valentina Guarneri, and Manuel Zorzi
Huge thanks to Stefano and Manuel from the Veneto Tumour Registry, and to Luigino from the Cancer Epidemiology Unit at the Centro Riferimento Oncologico di Aviano for the great collaboration and efforts!
And for intriguing correlative findings at the trial level, visit today the PS3-07-19 board to learn more about our study led by Davide Massa!”
You Can Also Read:
15 Posts Not to Miss from SABCS 2025, Part 1
20 Posts Not to Miss from SABCS 2025, Part 2
25 Posts Not to Miss from SABCS 2025, Part 3
